PDUFA III Deal Sets FY 2003 User Fee Funding Lower Than Bush Budget
This article was originally published in The Tan Sheet
Executive Summary
FDA and industry's negotiated PDUFA III user fees reflect a lower budget increase than originally proposed by the Bush Administration
You may also be interested in...
PDUFA III “Good Review Management Principles” Stress Early FDA Action
FDA's "Good Review Management Principles" guidance will recognize the need to complete second- and third-round reviews of NDAs before the action goal date under the Prescription Drug User Fee Act III
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands